Skip to main content
See every side of every news story
Published • loading... • Updated

Anvisa Records Two New Semiglutide Slimming Pens - Tribuna Do Norte

The National Agency of Sanitary Surveillance (Anvisa) approved on Tuesday (10) two new agonist injectable drugs of the GLP-1 receptor, popularly known as weight loss pens. These are: generic of semaglutide and Loryvia (similar product). In a note, Anvisa highlighted that both devices have as active principle to semaglutide and are indicated for the treatment of [...] The post Anvisa records two new weight loss pens of semaglutide first appeared …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

10 Articles

Anvisa approves two new semaglutide injection medicines in Brazil, including a generic and a similar one for type 2 diabetes.

tnh1.com.brtnh1.com.br
Reposted by
EBCEBC

The National Agency of Sanitary Surveillance (Anvisa) approved on Tuesday (10) two new agonist injectable drugs of the GLP-1 receptor, popularly known as weight loss pens. These are: generic of semaglutide and Loryvia (similar product). In a note, Anvisa highlighted that both devices have as active principle to semaglutide and are indicated for the treatment of [...] The post Anvisa records two new weight loss pens of semaglutide first appeared …

Now, Brazil already has 22 records of injectable medicines for the treatment of diabetes in 2026

The National Agency for Health Surveillance (Anvisa) approved the registration of two new injection pens based on semaglutin, the so-called weight loss pens, being a generic and similar version, marketed under the name Loryvia. The authorisations were published on Tuesday (10/11).According to the agency, the medicines are indicated for adults with type 2 diabetes mellitus who cannot adequately control the disease. To verify the efficacy and safe…

The National Agency of Health Surveillance (Anvisa) approved on Tuesday (10) two new agonist injectable drugs of the GLP-1 receptor, popularly known as weight-loss pens. They are: generic of semaglutide and Loryvia (like product).In a note, Anvisa highlighted that both devices have as active principle to semaglutide and are indicated for the treatment of diabetes. The two products have as matrix the product Ofozy and the records were granted to …

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

CNN Brasil broke the news in São Paulo, Brazil on Tuesday, November 10, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal